Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder (OAB) Clear all
Completed Not applicable Interventional Results available

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

NCT01369485
View directory record Official record
Conditions
Overactive Bladder
Interventions
(VERV™ System), Sham version of (VERV™ System)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Ease of Use Study of the FemPulse System

NCT06885099
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 2 Interventional

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

NCT05557279
View directory record Official record
Conditions
Overactive Bladder
Interventions
500 mg NDS-446
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Overactive Bladder Innovative Therapy Trial (OrBIT)

NCT00448175
View directory record Official record
Conditions
Overactive Bladder
Interventions
Urgent PC Neuromodulation System, Tolterodine
Device · Drug
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Jul 21, 2026, 11:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair

NCT02502838
View directory record Official record
Conditions
Overactive Bladder, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

eCoin for OAB Feasibility Follow-on Study

NCT03655054
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 21, 2026, 11:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

NCT02070042
View directory record Official record
Conditions
Overactive Bladder
Interventions
Omega 3 Fatty Acid, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 21, 2026, 11:34 PM EDT
Terminated Not applicable Interventional

Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol

NCT03559946
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
percutaneous tibial nerve stimulation (PTNS), Sham procedure
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

NCT00230789
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 21, 2026, 11:34 PM EDT
Completed No phase listed Observational

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

NCT05067478
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 21, 2026, 11:34 PM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 21, 2026, 11:34 PM EDT
Not listed Not applicable Interventional

Use of Repris Needle in Bladder Injection

NCT04982120
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Repris Needle
Device
Lead sponsor
Uro-1 Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cartersville, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jul 21, 2026, 11:34 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Jul 21, 2026, 11:34 PM EDT
Terminated Phase 2 Interventional

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

NCT06351683
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Interventions
MitoQ (mitoquinol mesylate), Placebo
Drug · Other
Lead sponsor
Iman Al-Naggar, PhD
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Utilization of the BIOWAVE Device to Treat Overactive Bladder

NCT01848366
View directory record Official record
Conditions
Overactive Bladder
Interventions
Biowave Treatment
Device
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 21, 2026, 11:34 PM EDT
Recruiting Not applicable Interventional

APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

NCT06797245
View directory record Official record
Conditions
Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
Interventions
RiSolve App, AUGS Patient Handouts
Device · Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
22 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT00912314
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
PTNS
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Early Phase 1 Interventional

IVES for Treatment of UUI and OAB

NCT02992509
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
EMED detruset(TM) intravesical electrical stimulation
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

NCT03556891
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
15
States / cities
Downey, California • Redwood City, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jul 21, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Placebo, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Jul 21, 2026, 11:34 PM EDT